CA
CTKB icon

Clearstead Advisors’s Cytek Biosciences CTKB Stock Holding History

Clearstead Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24
Closed -$122 – 2388
2025
Q4 		$122 Sell
24
-1,051
-98% -$4.88K ﹤0.01% 2487
2025
Q3 		$3.73K Buy
1,075
+448
+71% +$1.68K ﹤0.01% 2267
2025
Q2 		$2.13K Buy
+627
New +$2.09K ﹤0.01% 2309

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearstead Advisors's CTKB Position: Q1 2026 in Review

Clearstead Advisors sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 24 shares — an estimated $122 sold.

Clearstead Advisors first reported a position in CTKB in Q2 2025 and held it in 3 quarters. The position peaked at $3.73K in Q3 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Clearstead Advisors reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Clearstead Advisors sold 24 Cytek Biosciences shares in Q1 2026, an estimated $122.
  • Clearstead Advisors first reported a position in Cytek Biosciences in Q2 2025 and held it in 3 quarters.
  • Clearstead Advisors's Cytek Biosciences position peaked at $3.73K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.